Hypertensive Disorders in Pregnancy
CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction, Definitions and Classification</td>
<td>3</td>
</tr>
<tr>
<td>Treatment of Severe Pre-Eclampsia</td>
<td>4</td>
</tr>
<tr>
<td>• IV Labetalol Bolus</td>
<td>5</td>
</tr>
<tr>
<td>• IV Labetalol Infusion</td>
<td>6</td>
</tr>
<tr>
<td>• IV Hydralazine Bolus &amp; Infusion</td>
<td>6-7</td>
</tr>
<tr>
<td>Treatment of Eclampsia</td>
<td>8</td>
</tr>
<tr>
<td>Fluid Balance in Eclampsia and Severe Pre-Eclampsia</td>
<td>11</td>
</tr>
<tr>
<td>Treatment of Severe Hypertension in Pregnancy without Proteinuria</td>
<td>12</td>
</tr>
<tr>
<td>Timing of Birth</td>
<td>15</td>
</tr>
<tr>
<td>Treatment of Severe Hypertension in the Puerperium</td>
<td>16</td>
</tr>
<tr>
<td>Drugs and Dosage for breast feeding mothers</td>
<td>17</td>
</tr>
<tr>
<td>Treatment of Severe Hypertension Algorithm</td>
<td>18</td>
</tr>
<tr>
<td>Suggested Postnatal Care Algorithm</td>
<td>19</td>
</tr>
<tr>
<td>References</td>
<td>20</td>
</tr>
</tbody>
</table>

NEW to this guideline:

Extra sections prior to “Timing of Birth”

Anaesthetic input

Indications for referral to critical care
INTRODUCTION

Hypertensive disorders during pregnancy occur in women with pre-existing primary or secondary chronic hypertension, and in women who develop new onset hypertension in the second half of pregnancy.

They are a significant cause of morbidity and mortality in the UK and worldwide, with effects on both mother and baby. Pre-eclampsia in particular results in major perinatal, and long-term, complications. In the most recent triennial report 2014-2016 (published Nov 2018), it was a leading cause of material death (PET: 6th cause indirect deaths). Many deaths are related to poor management of severe hypertension and eclampsia. Foetal implications include increased incidence of placental abruption, preterm delivery and foetal growth restriction. These risks are not exclusive to pre-eclampsia.

DEFINITIONS

- **Chronic hypertension** that is present at the booking visit or before 20 weeks or if the women is already taking antihypertensive medication when referred to maternity services. This guideline in not intended to specifically address this condition

- **Gestational hypertension** (previously known as Pregnancy Induced Hypertension, PIH) is new hypertension presenting after 20 weeks without significant proteinuria.

- **Pre-eclampsia** is new hypertension presenting after 20 weeks with significant proteinuria. (SBP ≥140mmHg &/or DBP ≥90 mmHg on 2 occasions at least 4 hours apart, or any single reading of ≥160/110mmHg. Or severe hypertension not responding to treatment. Or with typical end organ disease/placental dysfunction

- **Proteinuria**: In pregnancy a spot urinary Protein: Creatinine ratio >30mg/mmol is significant. PCR is now the main urinary test (previously a 24 hr urine collection was used with >300mg/24 hours protein being significant. This is at least 2+ protein on urinalysis. This can sometimes be used when interpretation of PCR is complicated by renal disease/unstable renal function. If >5g/24 hours is considered severe). A PCR > 300mg.mol is considered “severe” and such levels can be seen in nephrotic syndrome. Always seek senior review in such cases.

- **Eclampsia**: Seizures occurring in pregnancy or the puerperium that cannot be attributed to other causes in a woman with pre-eclampsia (but it may appear unexpectedly in a patient with minimally elevated blood pressure and no proteinuria).

- **HELLP syndrome** is haemolysis, elevated liver enzymes and low platelet count. It is a manifestation of pre-eclampsia occurring in ~20% of severe cases. ELLP can occur without evidence of haemolysis
CLASSIFICATION OF HYPERTENSION

1. **Mild hypertension**: Systolic 140 – 149mm Hg and/or Diastolic 90 – 99 mmHg

2. **Moderate Hypertension**: Systolic 150- 159mmHg and/or Diastolic 100 – 109mmHg

3. **Severe Hypertension/PET**: Systolic ≥160 mm Hg and/or Diastolic ≥110 mm Hg

(Consider hypertension with ≥5 gm proteinuria in 24 hours Or Protein Creatinine Ratio ≥300mg/mmol as potentially severe disease)

NICE 2019 recommends offering treatment if >140/90. Target BP = 135/85 in all patients\(^2\).

SEVERE PRE-ECLAMPSIA

Introduction

*Severe pre-eclampsia is defined as severe hypertension which can be associated with evidence of end organ damage and biochemical and haematological impairment without seizure activity.*

Proteinuria is a common finding but can also be absent in some cases.

It can cause intracranial haemorrhage in the pregnant woman, resulting in death, or survival with a stroke. Severe hypertension which may be a component of severe pre-eclampsia requires treatment in its own right, regardless of other treatments which are in progress (for example, magnesium sulfate).

- In **severe pre-eclampsia** it is more important to **treat severe hypertension first**, before considering magnesium sulfate.
- In **eclampsia** it is more important to **prevent further seizures first**, before considering antihypertensive therapy.

Fulminating severe pre-eclampsia starts suddenly and progresses rapidly, and is dangerous, requiring urgent, intravenous treatment.

This Guideline describes the treatment of severe hypertension which may be a component of severe pre-eclampsia. For the treatment of severe hypertension *without Proteinuria*: Pages 13-15.
Diagnosis

If the systolic blood pressure is \( \geq 160 \text{ mm Hg} \), OR the diastolic blood pressure \( \geq 110 \text{ mm Hg} \), on TWO CONSECUTIVE OCCASIONS, 15 minutes apart, then severe hypertension is diagnosed, requiring intravenous treatment.

It is the systolic blood pressure which is the more important, since the risk of intracranial haemorrhage is associated with the degree of systolic hypertension. It is also associated with a proteinuria (see definitions above). Alternatively mild to moderate hypertension and proteinuria with any evidence of the following clinical features:

Clinical features of severe pre-eclampsia (in addition to hypertension and proteinuria) are:

- Severe headache
- Visual disturbances such as flashing lights or blurred vision
- Subcostal or Epigastric pain and / or vomiting
- Clonus \( \geq 3 \) beats
- Platelet count < 100,
- Liver tenderness or abnormal liver enzymes (ALT/ AST above 70 IU/L)
- HELLP Syndrome
- Papilloedema

Management of Severe Hypertension in severe pre-eclampsia

Treatment of sustained severe hypertension in severe pre-eclampsia is a medical emergency and the Consultant Obstetrician-on-call must be informed immediately along with the Consultant Anaesthetist and Unit Coordinator. (See page 19 Flowchart)

- Consider immediate Labetalol 200 mg orally (nifedipine if asthmatic)
- Move to LDRP room (preferably in ward 24)
- Insert wide bore I.V. access and send bloods for FBC, U & E, LFT, urate and G&S. (Coagulation screen if platelets below 100)
- Check B.P every 15 minutes
- Continuous oxygen saturation monitoring with a pulse oximeter (it will often give early signs of pulmonary oedema).
- Check for reflexes/clonus
- Catheterise and check urine dip stick for protein & send MSSU
- Strict fluid input and output chart, with hourly urine volumes
- Restrict overall fluid intake to 85 ml/hour (2L/24hr). Plasma-lyte has now replaced Hartmann’s solution. Plasma-lyte contains a very small amount of magnesium (Mg 1.5mmol/L in plasmalyte (0.375g/L), therefore, patients on MgSO4 infusions may require additional monitoring for evidence of Magnesium toxicity (NEW 2020).
- Perform a Cardiotocogram once stable
- Check Bishop score once stable
- USS for foetal assessment if clinically indicated
- Consider steroids if < 36 weeks gestation or SGA
- Document all medications clearly and promptly
- Intravenous labetalol and hydralazine are equally effective and either can be used. One drug should be used to its maximum dose before changing to the other. Start off with an intravenous bolus injection of labetalol or hydralazine. Care must be taken with IV hydralazine as it can rapidly cause hypotension.
  
  A&E in HM and MK do now stock IV hydralazine for patients who cannot be prescribed labetalol e.g. severe asthmatics

**Intravenous labetalol - Bolus injection (See Algorithm Pages 19 and 20)**

*CAN BE AN IRRITANT, SO MONITOR FOR EXTRAVASATION*

Aim for a target systolic blood pressure of less than 150mm Hg AND a target diastolic blood pressure of 80-100mmHg

(a) Give a bolus injection of **LABETALOL 50 mg intravenously over two minutes**.

(b) Wait for fifteen minutes. If the target blood pressure is not achieved give another bolus injection of **intravenous LABETALOL 50 mg over two minutes**.

(c) Wait for fifteen minutes. If the target blood pressure is not achieved start an intravenous infusion. Consider IV Hydralazine (page 7).

**Intravenous labetalol - Infusion**

(a) Each ampoule of labetalol contains 100 mg labetalol in 20 mls water. Place three ampoules in a 60 ml syringe - 300mg in 60 mls, i.e. **5 mg/ ml**.

(b) Start the syringe driver infusion at 40 mg per hour = **8mls per hour**

(c) Double the infusion rate every 30 minutes to maintain the systolic blood pressure below 150 mm Hg, AND the diastolic blood pressure at about 100 mm Hg.

(d) Once desirable B.P is maintained, reduce the rate of the infusion by one half.

(e) If the systolic blood pressure is below 140 mm Hg, OR the diastolic blood pressure is below 90 mm Hg, stop the infusion. Consider oral treatment.

(f) The maximum infusion rate is 160 mg per hour = 32 mls per hour.

**Contraindications to labetalol**

- Maternal bradycardia < 60 beats/ minute
- Asthma
Avoid rapid reductions in BP as this may result in complications for both mother and foetus

**Intravenous Hydralazine - Bolus injection**

The main **contraindication** to intravenous hydralazine is maternal tachycardia greater than 120 per minute.

Ensure there is additional venous access in the event of hypotension and consider 500mls crystalloid fluid simultaneously.

Avoid in patients with Systemic Lupus Erythematosus (SLE) and abnormal cardiac function

(a) **Reconstitution of Hydralazine 20mg amps:** reconstitute with 1ml water for injection and then further dilute with 19 ml sodium chloride 0.9% (NEW 2020). The resulting solution will contain 1 mg hydralazine per ml

(b) Inject 2 mg of the hydralazine solution every 3-5 minutes. Take the blood pressure every 2 minutes

(c) Administer/withhold dose of hydralazine according to the response of the blood pressure. Stop boluses when desired BP attained.

(d) Aim for a systolic blood pressure less than 150 mm Hg AND a diastolic blood pressure at about 100 mm Hg, then stop the injection. Consider oral medication.

- The dose of hydralazine which you will have to inject will vary from 2 mg to 20 mg for this response to occur.
- Occasionally injection of the whole 20 mg of hydralazine will fail to treat the severe hypertension. In this case, start an intravenous infusion of hydralazine.
- After you have finished the injection the blood pressure will fall a little further. This regimen will rarely, if ever, cause maternal hypotension or foetal distress.
- The hydralazine will act for 2-3 hours, after which severe hypertension may reappear. If the maternal heart rate is less than 120 per minute, intravenous hydralazine may be repeated. Significantly prolonged in renal impairment (up to 16h)

**Intravenous Hydralazine - Infusion**

*CAN BE AN IRRITANT, SO MONITOR FOR EXTRAVASATION*

a) Hydralazine comes in ampoules of 20 mg in a powder. Reconstitute each ampoule up to 20 mls n. See note above regarding reconstitution of Hydralazine

b) Add three reconstituted ampoules =
   60 mg in 60 mls to a syringe driver = **1 mg per ml**.

c) Start the infusion at 10 mls per hour = 10 mg per hour.
d) Double the dose every 20 minutes

e) Aim for the systolic blood pressure less than 150 mmHg AND the diastolic blood pressure to be about 100 mm Hg.

f) If the systolic blood pressure is less than 140 mm Hg OR the diastolic blood pressure is less than 90 mm Hg, stop the infusion.

g) The maximum dose rate is 40 mls = 40mg per hour.

**N.B.** The main contraindication to hydralazine is maternal tachycardia. If the maternal heart rate is more than 120 beats per minute, hydralazine cannot be used. Labetalol is preferred; this may reduce the blood pressure, and reduce the heart rate.

**Oral Nifedipine**

Usually intravenous labetalol alone, or intravenous hydralazine and labetalol, will be enough to treat severe hypertension, such that oral nifedipine will only occasionally be required. Oral nifedipine is also suitable as first line therapy in asthmatics when labetalol is contraindicated.

a) If hydralazine and labetalol fail to control severe hypertension, give oral NIFEDIPINE 10 mg. **In this instance use the immediate release preparation.**

b) Wait for thirty minutes. If the target blood pressure is not achieved give oral NIFEDIPINE 10 mg once more.

Note: The immediate release preparation is used only in this scenario. The prolonged released preparation is used for ongoing control of BP

**Magnesium Sulfate**

Consider treatment with Magnesium Sulfate if there are features of severe pre-eclampsia or if there is severe hypertension or severe pre-eclampsia in a patient who has previously had an eclamptic seizure.
TREATMENT OF ECLAMPSIA

Introduction

Eclampsia is the occurrence of a seizure(s) usually in a woman who has severe pre-eclampsia. Magnesium Sulfate is used to both Treat AND Prevent eclampsia.

It can be very harmful to the woman and her infant since the severe maternal hypoxia caused by the seizure may cause maternal and foetal death.

Aims - Treat seizures
- Control blood pressure
- Stabilise the mother
- Deliver the infant

Treatment of an Eclamptic Seizure

Inform the Consultant Obstetrician, Anaesthetist and Unit Coordinator

(a) In the Maternity Unit in Wishaw or in the A &E Department in Wishaw dial 2222 – obstetric emergency. State the Ward and Room number.

(b) In Hairmyres Day Assessment, Hairmyres A&E and Monklands A&E – ASK FOR THE CARDIAC ARREST TEAM.

(c) In Airdrie Day Assessment and Lanark Day Assessment – DIAL 999

(d) Place the woman in the left lateral position.

(e) Assess airway; insert oral airway if required. If continued seizure activity or compromised airway the anaesthetist will secure a definitive airway.

(f) Administer oxygen 15 litres a minute by a non-rebreathing trauma mask.

(g) Insert a large-bore intravenous cannula.

(h) Administer bolus dose of Magnesium Sulfate 4 grams intravenously diluted to 40 mls with Sodium chloride 0.9% over 10 minutes via Syringe Driver
- Each vial of magnesium sulfate (50%) contains 5 grams in 10 mls water.
- Dilute one vial Magnesium Sulfate to 50 mls with Sodium chloride 0.9%, then discard 10 mls, leaving 40 mls (4 grams MgSO4) of diluents remaining in the syringe
- Infuse this by Alaris Syringe Driver at a rate of 240 mls/hour (10 minutes).
- Use the BD Plastipak syringe with this Syringe driver

If IV access cannot be achieved give 5gms (1 vial, 10mls of 50%) magnesium sulphate intramuscularly (IM) (into the buttock).
(i) Take blood for FBC, U + E, LFTs, coagulation screen, glucose and G&S.

Prevention of further seizures

a) Start an intravenous infusion of **Magnesium Sulfate at a rate of 1 gram/ hour**.
   - Dilute 1 vial (5 g) of Magnesium Sulfate to 50 mls Sodium chloride 0.9% and infuse at 10 mls/hour via an Alaris Syringe Driver (takes 5 hours). BD Plastipak syringe.
   - Once prescribed by a doctor this can be made up and further infusion continued by any competent health care professional.

   In Airdrie Day Assessment and Lanark Day Assessment there are currently no infusion pumps nor is MgSO4 currently available.

   When available give the bolus dose of Magnesium Sulfate described above and transfer the woman as quickly as possible by the 999 ambulance (“blue light” ambulance).

b) The Magnesium Sulfate infusion should be maintained for **24 hours** from last fit.

c) A new syringe should be prepared every 24 hours

d) Measure oxygen saturation and maintain above 94%

e) Measure the respiratory rate every 15 minutes. If the respiratory rate is **< 12 breaths per minute**:
   - i. Stop the infusion of magnesium sulfate.
   - ii. Call the Anaesthetist on page 134.

f) If **respiratory arrest** occurs:-
   - i. Call 2222 – obstetric emergency.
   - ii. Ventilate with an Ambubag at 12 – 15 breaths per minute using 15 litres
   - iii. Oxygen per minute until intubation possible by experienced individual.
   - iv. Stop the Magnesium Sulfate infusion.
   - v. Give **Calcium Gluconate 1 gram intravenously over 5 minutes.**
     
     (10mls of 10% Calcium Gluconate (1 gram) IV over 5 minutes)

   N.B. There is generally no need to monitor magnesium concentrations, but these should be measured every six hours if -
   
a) **The infusion rate is 2 grams per hour**
b) The woman has hepatic or renal impairment or has weight ≤50 kg

General Measures

(a) Measure maternal pulse rate, blood pressure and respiratory rate every 15 minutes. If severe hypertension occurs, treat according to the related Guideline B. In eclampsia it is more important to *prevent further seizures first*, before considering antihypertensive therapy.

(b) Insert a Foley catheter and measure hourly urine volumes. If oliguria occurs, see Guideline D.

(c) Perform a cardiotocogram.

(d) Proceed to delivery, usually by Caesarean section, once stable

(e) Avoid the use of syntometrine or ergometrine at delivery

(f) The syringe driver typically used is the Alaris Syringe Driver. This requires the BD Plastipak syringe
FLUID BALANCE IN ECLAMPSIA AND SEVERE PRE-ECLAMPSIA

- In eclampsia and severe pre-eclampsia temporary oliguria is common up to 6 hours after birth. There is widespread arteriolar spasm which also affects the renal arterioles, resulting in reduced glomerular filtration rate.
- Some hours after delivery of the infant the vasospasm subsides and renal function usually returns to normal.
- Persistent renal failure in eclampsia and severe pre-eclampsia is rare.
- Moderate hypovolaemia is always present, and so intravenous fluids should not be too restricted.

**Regimen for Fluid Balance in Pre-Eclampsia & Severe Pre-Eclampsia**

1. Indwelling Foleys catheter, with hourly urine volumes.
2. Administer intravenous fluids, **2 litres/24 hours** – Plasma-lyte has now replaced Hartmann’s. Plasma-lyte contains a very small amount of magnesium. Remember to include other IV infusions such as MgSO4 in total calculation.
3. If the urine volume is > 20mls/ hour, persist with this regimen.
4. If the urine volume is < 20 mls/hour, oliguria is present. In this circumstance, send a specimen of blood and urine to the laboratory and ask for the urine/plasma osmolality ratio.
   - **(a)** A ratio of > 1.5 suggests that the renal tubules are able to concentrate urine and so acute tubular necrosis is unlikely. A diuresis can be expected in a few hours. Carry on with the intravenous fluid regimen described above.
   - **(b)** A ratio of < 1.5 suggests that renal tubular damage may have occurred. In this circumstance contact the Consultant Obstetrician on call, who will then contact the Consultant renal physician on call, for advice.

N.B. **Do not give intravenous furosemide.**
- This may cause a temporary diuresis which may be comforting to the Obstetrician, but will not improve the function of the renal tubules.
- It may be harmful, by depleting the blood volume further and exacerbating the hypovolaemia.

**Do not routinely insert a central venous pressure catheter.**
- Typically in eclampsia and severe pre-ecclampsia the central venous pressure is low, owing to the hypovolaemia, described above.
- Attempts to increase the central venous pressure by administration of intravenous fluids will increase the likelihood of acute pulmonary oedema.
- A central venous pressure catheter should be inserted only after discussion with the Consultant Anaesthetist on-call.
- If a central venous pressure catheter is inserted consider transferring the woman to the Adult Critical Care Unit (very few midwives have been trained in the care of women undergoing central venous pressure monitoring).
TREATMENT OF SEVERE HYPERTENSION IN PREGNANCY, WITHOUT PROTEINURIA

This guideline refers to treatment of severe hypertension in women without proteinuria. If severe hypertension occurs with significant proteinuria the diagnosis is severe pre-eclampsia. The woman should be treated according to pages 4-7 (Treatment of severe pre-eclampsia).

In the peripartum period absorption of oral drugs from the gastrointestinal tract is often reduced, therefore they are administered intravenously to every woman with severe hypertension, whether proteinuria is present or not, as in pages 5-10. See pages 5-10 for IV management.

The definition of severe hypertension is a sustained systolic blood pressure $\geq 160$ mm Hg, OR a sustained diastolic blood pressure $\geq 110$ mm Hg.

- Refer the woman to the Day Assessment Unit as soon as possible.
- At the Day Assessment Unit the blood pressure will be measured at least four times. The means of the systolic blood pressures and the mean of the diastolic blood pressures are calculated. If the mean of the systolic blood pressures is $> 160$ mm Hg, OR the mean of the diastolic blood pressures is $> 110$ mm Hg, sustained severe hypertension is present, requiring treatment.
- Treatment may be given successfully in the Maternity Day Assessment Units, although it is often quicker if the woman is admitted to the ward or triage.

First line is Labetalol now as per NICE CKS 2015 (3).

Labetalol

a) Start at Labetalol 100 mg 2– 3 times daily
a) Max dose Labetalol 600 four times daily
b) Max dose 2400 mg in 24 hours
c) Dose as per BNF

Contraindicated in Asthma or previous reaction. Consider Nifedipine.

Labetalol in pregnancy in patients with diabetes, hypo unawareness/ increased hypoglycaemia is not usually a problem, but should be considered.
Methyldopa

This can also be used safely in the first and second trimester in pregnancy. It acts on the central nervous system, to decrease sympathetic tone. It is an effective antihypertensive drug in pregnancy, and it is safe for the infant.

- The dose should be titrated according to the response.
- The blood pressure should be taken no more than four times a day.
- The dose should be increased every other day, if necessary.
- Don’t aim for a normal blood pressure.
- Aim for blood pressure $\leq 135/85$ mmHg

(a) Start by giving METHYLDOPA 250 mg 2-3 times a day.
(b) If necessary, increase the dose to METHYLDOPA 500 mg four times a day.
(c) If necessary, increase the dose to METHYLDOPA one gram three times a day.
(d) The dose increase needs to gradually over intervals of at least 2 days (as per BNF).

Once the dose is found which controls the blood pressure, the woman may be discharged from the ward.

Please Note

1. Methyldopa can cause depression and nightmares. If these symptoms develop, stop the drug, and start treatment with oral labetalol.

2. Do not take the blood pressure more than four times a day in the ward. Sometimes isolated readings occur which are much greater than 160 mm Hg systolic or 110 mm Hg diastolic, and these may lead to anxiety in the midwifery and medical staff, who will check the blood pressure every few minutes. This will lead to anxiety in the pregnant woman, resulting in worsening of the blood pressure, setting up a vicious circle. In severe hypertension in pregnancy without proteinuria, the risk of stroke caused by isolated episodes of severe hypertension is small, unlike the situation with severe hypertension with proteinuria.
WISHAW GENERAL HOSPITAL
WOMEN’S SERVICES DIRECTORATE

Nifedipine SR

Start at 10 mg slow release twice daily

Max dose is 40 mg SR twice daily

**NOTE: This is different to the ordinary release which is 8 hourly**

Nifedipine off license use in pregnancy

If patient has chronic hypertension, consider restarting her pre-pregnancy medications postnatally unless contraindicated by Breastfeeding. Contact pharmacy for advice if needed.

Anaesthetic Input – Analgesia & Anaesthesia (NEW 2020)

The majority of women with severe pre-eclampsia will benefit from neuraxial analgesia in labour, through prevention of the hypertensive response to pain, and the resulting sympathetic block contributing to the overall anti-hypertensive strategy. In addition, an indwelling epidural catheter enables the provision of surgical anaesthesia should operative delivery become necessary. When central neuraxial blockade is contraindicated, i.v. opioids provide an appropriate alternative, with remifentanil patient controlled analgesia gaining popularity. Postpartum analgesia will vary depending on the mode of delivery but may include i.v. opioids, abdominal wall nerve blocks or wound infiltration and simple analgesics such as paracetamol.

Central neuraxial blockade is the anaesthetic technique of choice for the majority of pre-eclamptic women requiring operative delivery. Spinal, epidural and CSE are all used successfully with no evidence in favour of one particular technique. Invasive monitoring is useful especially if the mother is already requiring magnesium sulphate and i.v. anti-hypertensives. General anaesthesia may be necessary if regional techniques are contraindicated due to clotting abnormalities.

**Indications for referral to critical care (NEW 2020)**

Following discussion with the anaesthetic and obstetric consultants on-call and the labour ward sister, it will be decided which patients can be managed in the Ward 24 HDU room and those who should be referred and transferred to the Adult Critical Care Unit (ACCU). Potentially Level 2 patients (Severe pre-eclampsia with any of the following complications e.g. eclampsia, evidence of heart failure, abnormal neurology) could be managed in-situ and Level 3 (Severe pre-eclampsia and needing invasive ventilation) transferred to ACCU.


TIMING OF BIRTH

Women with **chronic/gestational hypertension**

- If blood pressure is lower than 150/100mm Hg with or without antihypertensive treatment, do not offer birth before 37 weeks.
- For women with refractory severe hypertension, offer birth before 37 weeks after a course of antenatal steroids has been completed.
- Offer birth to women whose diastolic blood pressure is greater than 95 mmHg with or without antihypertensive treatment after 37 + 0 weeks.
- Offer birth to women after 39 + 0 weeks with stable controlled hypertension
- Consider birth at any gestation when there is evidence of impending foetal death.
  - May require a detailed discussion with neonatology input at limits of viability

Women with **Pre-eclampsia**

- Manage conservatively until 34 weeks
- Consultant Obstetric staff to advise and document biochemical, haematological and clinical thresholds (mother and baby) for birth before 34 weeks
- Offer birth before 34 weeks after discussion with neonatal and anaesthetic teams and a course of antenatal steroids completed if:
  - Severe hypertension develops refractory to treatment.
  - Maternal haematological, biochemical or clinical indicators develop (see consultant plan)
  - Foetal indications develop
- Advise birth after 34 weeks for severe pre-eclampsia once BP controlled (+ course of antenatal steroids complete if appropriate)
- Offer birth at 34+0 to 36+6 for mild/moderate pre-eclampsia, depending on maternal and foetal condition, risk factors, availability of neonatal care
- Advise birth within 24-48 hours for mild/moderate pre-eclampsia after 37 +0 weeks
TREATMENT OF SEVERE HYPERTENSION AFTER 48 HOURS AFTER DELIVERY

The post-natal hypertension of pre-eclampsia subsides after 7-10 days. Anti hypertensive therapy may be required for that time. Aim to keep BP below 150/100 mm Hg. Consider reducing antihypertensive treatment if BP falls below 140/90 (2).

Avoid methyldopa

- Methyldopa in the puerperium may precipitate post-natal depression.
- Stop methyldopa within 2 days of birth and restart antihypertensive the woman was receiving prior to planning pregnancy.

If need for once daily antihypertensive then

a) Try oral ATENOLOL 100 mg once daily. NICE – IF new hypertension: enalapril (5-20mg twice daily) is first line, except for women of Black African or Caribbean family origin where nifedipine/amlopidine are better first line. (NEW)

b) If pre-pregnancy hypertension consider restarting previous meds if appropriate.

c) If this is ineffective, add adding either enalapril (5-20mg twice daily)or amlodipine (5mg) to current single agent (NEW)

d) NICE 3rd line is add betablocker to combination or swap 1 for labetalol or atenolol

- Consider daily bloods for 72 hours post delivery
- Consider for discharge only if bloods and BP are normal or improving.

See table for reference of Anti hypertensives in breast feeding women.

- In women who have pre-eclampsia and remain on antihypertensive treatment 2 weeks after discharge from hospital, perform medical review.

Refer women who have had pre-eclampsia and who still require antihypertensive treatment at the postnatal visit (6-8 weeks after the birth) for specialist assessment.

NOTE:

Potential interaction between nifedipine and beta blockers: possible severe hypotension and heart failure
Drugs and dosages for Breastfeeding Mothers

Drug*  Dose Comments
Recommended by NICE and widely used in UK

β blockers:

**Labetalol** 100-600 mg 2-3 times daily only small quantities detected in breast milk

**Atenolol** 25-100 mg once daily
Thirdline as per NICE 2019. Use for women who require once daily formulation

Calcium channel antagonists:

Amount in breast milk too small to be harmful; manufacturer suggests avoid but widely used without reports of neonatal side effects

**Nifedipine SR** 10-20 mg twice daily

**Amlodipine** 5-10 mg once daily

**Nifedipine Long Acting** 20-30 mg once daily. Increasing if necessary to 90mg once daily
Both can be used as second line use for women who require once daily formulation; amount in breast milk too small to be harmful; manufacturer suggests these drugs should be avoided but used in clinical practice without report of harm

Angiotensin converting enzyme (ACE) inhibitors:

NICE 2019 suggests first line (except in Black African or Caribbean origin). Very small amount in milk Can be used in women who were previously taking an ACE inhibitor when other first choice agents cannot be used or cardiac/renal protection is needed; excreted into breast milk in low concentrations but amount probably too small to be harmful

**Enalapril** 5-20 mg twice daily

Contraindicated

Other ACE inhibitors and angiotensin receptor blockers - Not recommended
Minimal data on use during lactation; manufacturers suggest that it should be avoided
Diuretics - Not recommended Produce excessive thirst in breastfeeding women; large doses may suppress lactation

*None of these drugs are licensed for use in breast feeding.

NICE National Institute for Health and Clinical Excellence
Treatment of Severe Hypertension (IV Therapy may be used first line)

Also see pages 6-7 Hydralazine Guidelines (may be used as first line in asthmatics)

1. Systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 110 mmHg on 2 separate readings 15 minutes apart

   No

   Asthmatic

   Yes

   Labetalol 200 mg orally

   Nifedipine capsule 10 mg orally (not sublingual)

   Recheck BP in 15 minutes

   1 is BP below threshold

   Yes

   No

   Labetalol 200 mg orally

   Recheck BP in 15 minutes

   1 is BP below threshold?

   Yes

   No

   Labetalol 200 mg orally

   Recheck BP in 15 minutes

   1 is BP below threshold?

   Yes

   No

   Maintenance dose

   Labetalol 200mg 2-3 x day

   1V labetalol (5mg/ml)

   Loading: 10ml (50 mg) over 2 minutes. Repeat Bolus after 15 minutes if required

   Maintenance: Start infusion at 8 ml/hour. Double infusion rate every 30 minutes until BP controlled

   Max infusion rate 32 ml/hour

   Maintenance dose

   Labetalol 200mg 2-3 x day

   1V labetalol (5mg/ml)

   Loading: 10ml (50 mg) over 2 minutes. Repeat Bolus after 15 minutes if required

   Maintenance: Start infusion at 8 ml/hour. Double infusion rate every 30 minutes until BP controlled

   Max infusion rate 32 ml/hour

   IV hydralazine (1mg/ml)

   Loading: 2ml (2mg) every 2 minutes with BP checks and titrate to BP response.

   Usually target BP achieved between 2-20mg

   Hydralazine

   Maintenance: Start infusion at 10mg/hr titrate to systolic BP 140-150 mmHg

   Usual rate 2-3 ml/hour

   Max infusion rate 40 ml/hour

   Reduce rate if significant adverse effect or maternal pulse > 120 beats/minutes

   Aim to keep BP < 135/85 mmHg

   Caution: All three drugs have cumulative effect (peak at 30 minutes) and all three interact with magnesium sulphate.

   Labetalol does increase the maternal blockage of magnesium sulphate.
Suggested Postnatal Care with Hypertensive Patient

**DAY 1-2 POST PARTUM: CHRONIC OR GESTATIONAL HYPERTENSION & CRITERIA FOR DISCHARGE MET**

- Check blood pressure at least daily
- Assess for pre-eclampsia
- Blood Pressure ≥160/110 mm Hg
  - Refer back to general hospital assessment unit within 24 hours
- Blood pressure ≥150/100 mm Hg or blood pressure ≥140/90 mm Hg and/or symptoms of pre-eclampsia present
  - Diastolic blood pressure 90-99 mm Hg and no symptoms of pre-eclampsia: monitor blood pressure daily; if persistent ensure medical review and consider starting antihypertensives.
  - Inform woman to seek medical advice if she develops symptoms of pre-eclampsia.

**NEWLY IDENTIFIED HYPERTENSION**

- Blood Pressure ≥160/110 mm Hg
  - Readmit to Hospital

**WEEK 2 POST PARTUM**

- Check blood pressure as clinically indicated if drugs have changed after delivery. Check weekly until drugs have stopped. Recheck weekly for two weeks after drugs have been stopped.
- Repeat platelet count, transaminases or serum creatinine if abnormal as clinically indicated.

- Check urinalysis, blood pressure, and repeat blood tests if not previously returned to normal
- Still requires antihypertensives
  - No proteinuria
  - Chronic hypertension before pregnancy
  - Review antihypertensive treatment and monitoring in primary care as per NICE guidelines
- Gestational hypertension or antenatal pre-eclampsia
  - Proteinuria ± requires antihypertensives ± blood tests remain normal
  - ≥1+ protein only
  - Repeat 3 months postpartum
  - ≥1+ protein
  - Offer Specialist assessment

**WEEK 6 POST PARTUM**

- Normal blood pressure
  - No proteinuria
  - Inform all women of future cardiovascular and future pregnancy risk
REFERENCES

1. 6th MBRRACE-UK report 2015-17. Saving Lives, Improving Mothers’ Care Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2015-17.


5. Diagnosis and Management of Gestational Hypertension and Preeclampsia. Sibai B.H. Best Practise. VOL. 102, NO. 1, JULY 2003 (ACOG)

Originator: Dr J M Grant
Reviewed: May 2011, Dr Surindra Maharaj
Reviewed: December 2016. Dr Surindra Maharaj, Dr Ujwal Jadhav
Reviewed Dr Adam Livingston (Anaesthetics) Dr S Maharaj (Obs)
December 2019
Ratified: Clinical Effectiveness Maternity Group (Final June 2020)
Review Date: June 2023